NCT02229071View on ClinicalTrials.gov

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

October 30, 2016

Conditions
HCC
Interventions
DRUG

Donafenib(200mg)

Donafenib 200mg,bid,po

DRUG

Donafenib(300mg)

Donafenib 300mg,bid,po

Trial Locations (1)

610041

West China Hospital,SCU, Chengdu

All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT02229071 - Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter